Overview
This one-hour webinar will address:
- Aspects of PD-L1 IHC as a biomarker for PD1-PD-L1 axis immunotherapy.
- The basis for its use.
- The practical challenges faced in its development and application.
- There will also be some discussion of other emerging biomarkers for this indication.
After viewing this program, attendees will:
- Understand the basis and biology of the PD-L1 IHC biomarker;
- Understand the issues around PD-L1 test 'harmonization'.
- Be aware of the emerging alternative or additional biomarkers in this space.
Keith Kerr
Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, UK.
For any inquiries, please contact meetings@iaslc.org.
After viewing this program, attendees will:
- Understand the basis and biology of the PD-L1 IHC biomarker;
- Understand the issues around PD-L1 test 'harmonization'.
- Be aware of the emerging alternative or additional biomarkers in this space.
Keith Kerr
Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, UK.
For any inquiries, please contact meetings@iaslc.org.